Aspira Women's Health develops and commercializes diagnostic tests that address unmet needs in gynecologic oncology and women’s health.
Aspira Women's Health develops and commercializes high-value, multi-marker, diagnostic tests that address unmet needs in gynecologic oncology and women’s health. The company is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women.Its OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiXSM testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. They focus on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment.Aspira Women's Health was founded in 1993 and is headquartered in Austin, Texas, USA.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 23, 2014 | Post-IPO Equity | $10.50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Birchview Fund | — | Post-IPO Equity |